StockNews.AI
YMAB
StockNews.AI
6 hrs

Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

1. Y-mAbs is being sold to SERB Pharmaceuticals for $8.60 per share. 2. Law firm KSF is investigating if the offer undervalues Y-mAbs. 3. Shareholders are urged to assess their legal rights regarding the sale. 4. The transaction is structured as a tender offer, with urgency implied. 5. KSF's investigation may indicate shareholder dissatisfaction with the offer.

3m saved
Insight
Article

FAQ

Why Bearish?

Investigations into undervaluation might deter investors, lowering market confidence. Historical similar situations, such as with Snap Inc., saw stock prices decline during investigations about acquisition valuations.

How important is it?

The investigation highlights potential shareholder discontent, crucial for market perception of the acquisition. Investor reactions to perceived undervaluations can significantly impact stock performance.

Why Short Term?

Immediate concerns from the investigation could influence stock volatility in the near term. Previous precedent shows swift market reactions upon such news.

Related Companies

SERB
NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB) to SERB Pharmaceuticals. Under the terms of the proposed transaction, shareholders of Y-mAbs will receive $8.60 in cash for each share of Y-mAbs that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-ymab/ to learn more. Please note that the transaction is structured as a tender offer, such that time may be of the essence. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. Kahn Swick & Foti, LLC1100 Poydras St., Suite 960New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Related News